Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Wai Chun Bio-Technology Ltd. ( (HK:0660) ) has shared an announcement.
Wai Chun Bio-Technology Limited has provided an update on remedial measures related to earlier non-compliance connected with a loan agreement, focusing on strengthening governance and regulatory adherence. The company has appointed a new chief financial officer in February 2026 to guide directors on compliance matters, tighten internal controls, and oversee the ongoing implementation of the remedial measures, signalling a more robust approach to risk management.
In addition, Wai Chun has organized internal training for all directors, senior management, and relevant personnel to deepen their understanding of the Hong Kong Listing Rules, particularly Chapters 13, 14 and 14A. These steps indicate a concerted effort to rectify past shortcomings, enhance oversight, and reassure regulators and investors that the company is improving its corporate governance and compliance framework.
More about Wai Chun Bio-Technology Ltd.
Wai Chun Bio-Technology Limited is a Hong Kong-listed company incorporated in the Cayman Islands and traded under stock code 660. The group operates under a board led by chairman and chief executive officer Lam Ka Chun, supported by independent non-executive directors, and is subject to the compliance and disclosure regime of the Hong Kong Listing Rules.
Average Trading Volume: 141,231
Technical Sentiment Signal: Buy
Current Market Cap: HK$46.4M
See more insights into 0660 stock on TipRanks’ Stock Analysis page.